Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Radiation.

Linköping University, Linköping, Sweden.

Survival: monthsCountry:Sweden
Toxiciy Grade:5City/State/Province:Linköping
Treatments:RadiationHospital:Linköping University
Drugs:Journal:Link
Date:Sep 2012

Description:

Patients:
This phase 3 study involved newly diagnosed glioblastoma patients, all older than 60 years, who were divided into three separate treatment groups. Group A was composed of 93 patients with a median age of 70 years and 59% male. Group B had 98 patients with a median age of 70 years and 51% male. There were 100 patients in group C with a median age of 70 years and 68% male.

Treatment:
Patients in group A were treated with the chemotherapy agent temozolomide.
Patients in group B were treated with hypofractionated radiotherapy.
Patients in group C were treated with standard radiotherapy.

Toxicities:
There was one treatment-related death in group A due to bleeding. Grade 4 neutropenia and thrombocytopenia were also reported.

The most severe toxicities in group B were of grade 4 and included seizures and fatigue.

There was one treatment-related death due to infection reported in group C. Grade 3 seizures were also reported.

Results:
The median overall survival rates for groups A, B, and C were 6.0, 8.3, and 7.5 months, respectively.

Support:
This study was partially supported by Merck.

Correspondence: Dr. Annika Malmström; email: [email protected]



Back